OBJECTIVES: NASH is a progressive form of Non-alcoholic Fatty Liver Disease that can lead to cirrhosis, hepatocellular carcinoma and liver failure. Humanistic burden remains poorly defined, thus the aim of this analysis is to report the burden among NASH patients.

METHODS: Data for this non-interventional study come from GfK’s NASH-Atlas database and were collected July-November 2017 among physicians managing NASH patients in the US, France and Germany. Physicians provided a paper survey to their next 5-7 eligible patients for voluntary self-completion. Patients completed the Chronic Liver Disease Questionnaire (CLDQ) with recall 2 weeks across 6 domains (abdominal, fatigue, activity, systemic, emotion and worry) and scores ranging from 1-most to 7-least impairment and the EQ-5D-5L questionnaire.

RESULTS: CONCLUSIONS: Whilst NASH is typically characterized as a ‘silent’ disease, over two-thirds of patients reported symptoms and HRQoL scores indicated impairment. Further research is needed to explore the clinical relevance and patient view as well as assess the potential improvement by future therapies.